Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
Diana Simão, Kevin Zarrabi, José Leão Mendes, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1412-1412
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment
Justyn Fine, Bunyarit Meksiriporn, Jiacheng Tan, et al.
Annual Review of Chemical and Biomolecular Engineering (2024) Vol. 15, Iss. 1, pp. 105-138
Closed Access | Times Cited: 5
T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma
Robin Reschke, Alexander Enk, Jessica C. Hassel
Pharmaceutics (2024) Vol. 16, Iss. 8, pp. 1046-1046
Open Access | Times Cited: 5
T-Cell Engagers in Prostate Cancer: Promise, Challenges, and the Road Ahead
Tarek M. Taha, Kira‐Lee Koster, Johann S. de Bono
European Urology (2025)
Closed Access
Nonshrinkable Thermosensitive Hydrogels Combined with Bispecific Anti-PSMA/CD3 T-Cell Engager for Effective Against Tumors in Mice Model
Pu-Sheng Wei, Po-Yu Chou, Hong‐Yuan Hsu, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 3083-3111
Open Access
Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
Roa Alsajjan, Warren Mason
Current Oncology (2023) Vol. 30, Iss. 9, pp. 8501-8549
Open Access | Times Cited: 14
T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer
Julia Palecki, Amman Bhasin, Andrew Bernstein, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 4
Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches
Adam Khorasanchi, Feng Hong, Yuanquan Yang, et al.
Cancer Drug Resistance (2025)
Open Access
Future Landscape of Anti-Claudin 18.2 Antibodies in Gastric Adenocarcinoma
Wendy Covert, Jane E. Rogers
Antibodies (2025) Vol. 14, Iss. 1, pp. 26-26
Open Access
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors
Ravit Geva, María Vieito, Jorge Ramón, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 10
Open Access | Times Cited: 3
Developability considerations for bispecific and multispecific antibodies
Alaa Amash, Gesa Volkers, Patrick Farber, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 3
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges
A. Raja, Abhishek Kasana, Vaishali Verma
Molecular Biotechnology (2024)
Closed Access | Times Cited: 3
Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2
Lucía Paniagua‐Herranz, Irene Moreno, Cristina Nieto‐Jiménez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2222-2222
Open Access | Times Cited: 2
Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future
Harriet Lampe, Laura Tam, Aaron R. Hansen
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer
Parveen Kumar Goyal, Kavita Sangwan
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 11, pp. 1337-1344
Closed Access | Times Cited: 2
Targeting Prostate Cancer Using Bispecific T-Cell Engagers against Prostate-Specific Membrane Antigen
Gargi Das, J. Ptáček, Barbora Havlínová, et al.
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 11, pp. 1703-1714
Open Access | Times Cited: 4
Current Advances in Bispecific T Cell–Engaging Therapies
Emmanuel Owusu Ansah, Bernard Ansong Nyarko
(2024)
Open Access | Times Cited: 1
HER2-CD3-Fc Bispecific Antibody-Encoding mRNA Delivered by Lipid Nanoparticles Suppresses HER2-Positive Tumor Growth
Liang Hu, Shiming Zhang, John Sienkiewicz, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 808-808
Open Access | Times Cited: 1
Recent Advancements in Cell-Based Therapies in Melanoma
George Nassief, Angela Anaeme, Karen Moussa, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 9848-9848
Open Access | Times Cited: 1
Immunome profiling in prostate cancer: a guide for clinicians
Luís Manso, Arántzazu Alfranca, Ignacio Moreno-Pérez, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Immunotherapy combinations for metastatic castration-resistant prostate cancer – failed trials and future aspects
Susan F. Slovin
Current Opinion in Urology (2023) Vol. 33, Iss. 5, pp. 390-395
Closed Access | Times Cited: 2
Tumor-associated antigen targets for novel immune-based strategies in prostate cancer
Amman Bhasin, Patrick Mille, Aditya Eturi, et al.
Journal of Translational Genetics and Genomics (2024) Vol. 8, Iss. 1, pp. 55-76
Open Access
DARPin-fused T cell engager for adenovirus-mediated cancer therapy
Patrick C. Freitag, Jonas Kolibius, Ronja Wieboldt, et al.
Deleted Journal (2024) Vol. 32, Iss. 3, pp. 200821-200821
Open Access
Bispecific T-Cell Engagers (BiTEs) in Immunotherapy
Mohsen Sheykhhasan, Anita Silas La’ah, Amirhossein Ahmadieh-Yazdi, et al.
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2024), pp. 205-234
Closed Access
Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma
Sharon H. Choi, Yu‐Wei Chen, Justine Panian, et al.
The Oncologist (2024)
Open Access
Mechanisms of resistance of antibody-drug conjugates—Obstacles to overcome
Yanitsa Davidkova, Milan Jagurinoski, Margarita Guenova
Elsevier eBooks (2024), pp. 257-273
Closed Access
Page 1 - Next Page

Scroll to top